PIQUR Therapeutics - Articles and news items


New study to investigate PQR309 and eribulin in triple-negative breast cancer

Industry news / 17 February 2016 / Victoria White

Eisai and PIQUR Therapeutics are to collaborate to conduct the Phase I/IIb clinical study of PIQUR’s PQR309 in combination with Eisai’s eribulin…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...